An Epitope Tagging Vector for Gene Expression in Mammalian Cells
Use tag-specific antibodies to study expressed genesAn Epitope Tagging Vector for Gene Expression in Mammalian Cells
Tanya Hosfield • Quinn Lu
Stratagene
The pCMV-Tag1 vector is an epitope tagging vector designed for gene
expression in mammalian cells. A target gene inserted into the pCMV-Tag1 vector
can be tagged with the FLAG ® epitope¨¨
(N-terminal, C-terminal or internal tagging), the c-myc epitope (C-terminal) or
both the FLAG (N-terminal) and c-myc (C-terminal) epitopes. Tagged constructs
generated in the pCMV-Tag1 vector can be transfected into mammalian cells, and
the tagged gene product can be easily characterized using commercially
available, tag-specific antibodies.
The epitope tagging technique involves fusion of a protein of interest to a
peptide-epitope that is recognized by a readily available antibody. In this
technique, expression of the fusion protein is monitored using a tag-specific
antibody, allowing a new protein to be studied without generating a new,
specific antibody to that protein. Epitope tagging can be used to localize gene
products in living cells, identify associated proteins, track movement of
fusion proteins within the cell, or characterize new proteins by
immunoprecipitation.1-3
pCMV-Tag1 Vector for Epitope Tagging

Stratagene’s pCMV-Tag1 vector is a general mammalian expression
vector that contains the FLAG and c-myc epitopes positioned for either
terminal or internal tagging of a target protein. The pCMV-Tag1 vector
(figure
1) is derived from the pCMV-Scriptä
vector4 and contains sequences for the FLAG and c-myc epitopes.
These specific epitope tags are small, not interfering with the function
of the target protein, and highly immunoreactive. The FLAG epitope is
a synthetic epitope that consists of eight amino acid residues (DYKDDDDK).5
The c-myc epitope is derived from the human c-myc gene and contains
10 amino acid residues (EQKLISEEDL).6 In addition to the epitope
tag sequences, the pCMV-Tag1 vector contains features for expression of
fusion proteins in eukaryotic cells. The cytomegalovirus (CMV) promoter
allows constitutive expression of the cloned DNA in a wide variety of
mammalian cell lines. The neomycin-resistance gene is under control of
both the prokaryotic b-lactamase promoter to
provide kanamycin resistance in bacteria and the SV40 early promoter to
provide G418 resistance in mammalian cells. The multiple cloning site
(MCS) of the pCMV-Tag1 vector is arranged to allow a variety of cloning
strategies to be used, resulting in C-terminal, N-terminal or internal
tagging of the protein of interest. A Kozak consensus sequence of GCC(A
or G)CCATGG7 provides optimal expression of the fusion protein
when the N-terminal FLAG epitope tag is used. Other cloning options, which
require fusion proteins to include their own translational start sequence,
are also possible.
Cloning Strategies for Epitope Tagging

Epitope Tag
Tag Location
Cloning Site
Kozak Sequence
A
FLAG
C-terminus
MCS 1
Insert supplied
B
FLAG
N-terminus
Bgl II
Vector supplied
C
FLAG and
c-myc
N and
C-termini
Bgl II and MCS 2
Vector supplied
D
c-myc
C-terminus
MCS 1 and 2
Insert supplied
E
FLAG
Internal
MCS 1 and Bgl II
Insert supplied
F
No tag
N/A
MCS 1 or MCS 1 and 2
Insert supplied
A gene of interest can be efficiently cloned into the pCMV-Tag1 vector
for terminal tagging with either the FLAG or c-myc epitopes or internal
tagging with the FLAG epitope. With these choices, researchers can optimize
the tagging position for each protein they study. The cloning strategies
for various tagging choices are summarized in figure
2.
Expression in the pCMV-Tag1 Vector

The firefly luciferase gene was cloned into the Bgl II and Xho
I sites of the pCMV-Tag1 vector such that the luciferase protein was
tagged with the FLAG epitope at the N-terminus and the c-myc epitope at
the C-terminus. We chose the luciferase gene because it can be assayed
both enzymatically and immunologically. This construct was transiently
transfected into Chinese hamster ovary (CHO) cells, and the cell lysates
were assayed for luciferase activity. The results of these luciferase
assays (figure
3) demonstrate that luciferase tagged with both FLAG and c-myc is
biologically active. Control transfections, with the reagents alone or
the pCMV-Tag1 vector without the luciferase insert, show low background
levels.
Figure 3
To demonstrate the easy detection of the epitope tags, we performed Western
blot analyses of cell lysates derived from cells transfected with the
pCMV-Tag1 vector and the pCMV-Tag1 vector with the luciferase insert (figure
4). Aliquots of these samples were simultaneously loaded and electrophoresed
in three separate gels.
Figure 4
The three gels were then probed individually with
either anti-luciferase, anti-FLAG or anti-c-myc antibodies. The results
indicate that the fusion protein, composed of FLAG-luciferase-c-myc, is
easily detected by Western blot analysis.
In order to demonstrate G418 resistance in the pCMV-Tag1 vector, we used
Stratagene’s Mammalian Transfection Kit to obtain stable CHO cell lines
containing either the pCMV-Tag1 vector or the pCMV-Tag1 vector with the luciferase insert. For the cells transfected with the pCMV-Tag1 vector
containing the luciferase gene, the luciferase assay was used to verify the
presence of the fusion protein (data not shown).
Conclusions
The pCMV-Tag1 expression vector incorporates the small and highly
immunoreactive FLAG and c-myc epitopes into constructs for N-terminal,
C-terminal and internal tagging. These tags eliminate the need for raising
specific antisera to study a target gene. The epitope tags can be easily
detected in transfected cells using well-characterized, commercially available
antibodies. The pCMV-Tag1 vector offers a fast, versatile and reliable method
for analyzing the function of gene products in vivo.
Acknowledgments
We would like to thank Denise Wyborski, Cathy Chang, Xu Li, Chao-Feng Zheng, Wei-Ping Yang, Phyllis Frosst and the members of the Gerace lab at TSRI for suggestions, discussion and materials.
REFERENCES
-
Kolodziej, P.A., and Young, R.A. (1991) Methods Enzymol.
194: 508-519.
-
Cravchik, A., and Matus, A. (1993) Gene 137:
139-143.
-
Sells, M., and Chernoff, J. (1995) Gene 152:
187-189.
-
Hosfield, T., Padgett, K., Sanchez, T., and Lu, Q. (1997) Strategies
10: 68-69.
-
Hopp, H.P., et al. (1988) Biotechnology 6:
1204-1210.
-
Evan, G.I., et al. (1985) Mol. Cell Biol. 5:
3610-3616.
-
Kozak, M. (1991) J. Biol. Chem. 266: 19867-19870.